Other kinase fusions in addition to ALK were identified in IMT, which were targeted with tyrosine kinase inhibitors, through the next-generation sequencing- (NGS-) based genomic assay [16]. The gene discussed is ALK; the disease is inflammatory myofibroblastic tumor.